Arhalofenate and Febuxostat Drug-Drug Interaction Study in Gout

Phase 2, open-label trial of arhalofenate in gout and hyperuricemia (2 cohorts), sponsored by Gilead Sciences. Primary endpoints: Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL at 43 days, Proportion of patients achieving an sUA reduction of >= 2.0, >= 3.0, and >= 4.0 mg/dL from baseline at 43 days and 5 more. Started Aug 2014; status: completed.